Tissue Regenix Group Plc
Non- Executive Director Share Purchase
York, 23 October 2015 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company"), the regenerative medical devices company, today announces that on 21 October 2015 Alan Miller, Non-Executive Director of Tissue Regenix, acquired 400,000 ordinary shares of 0.5 pence at a price of 16.75p per share.
Following this transaction Alan Miller holds 21,886,988 ordinary shares which represents a total of 2.88% of the Company's issued share capital.
For Further Information
Tissue Regenix Group Plc: +44 19 0456 7609
Caitlin Pearson
Corporate Communications Officer
[email protected]
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44 207 353 4200
James Macey White
Matt Low
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
